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Insulin-dependent (type 1) diabetes mellitus is a metabolic disease with a complex multifactorial etiology and a
poorly understood pathogenesis. Genetic and environmental factors cause an autoimmune reaction against pan-
creatic -cells, called insulitis, confirmed in pancreatic samples obtained at autopsy. The possibility to noninvasively
quantify -cell mass in vivo would provide important biological insights and facilitate aspects of diagnosis and
therapy, including follow-upof islet cell transplantation.Moreover, theavailabilityof anoninvasive tool toquantify
the extent and severity of pancreatic insulitis could be useful for understanding the natural history of human
insulin-dependent(type1)diabetesmellitus, toearlydiagnosechildrenatrisktodevelopovertdiabetes,andtoselect
patients to be treated with immunotherapies aimed at blocking the insulitis and monitoring the efficacy of these
therapies. In this review,weoutlinethe imagingtechniquescurrentlyavailable for invivo,noninvasivedetectionof-cell
mass and insulitis. These imaging techniques includemagnetic resonance imaging, ultrasound, computed tomography,
bioluminescence and fluorescence imaging, and the nuclear medicine techniques positron emission tomography and
single-photon emission computed tomography. Several approaches and radiopharmaceuticals for imaging -cells and
lymphocytic insulitis are reviewed in detail. (Endocrine Reviews 33: 892–919, 2012)
I. Introduction
II. Radiological Techniques for Imaging BCM and Insulitis
A. Magnetic resonance imaging
B. Ultrasonography
C. Computed tomography
D. Concluding remarks on radiological techniques
for imaging BCM and insulitis
III. Optical Imaging Techniques for Imaging BCM and
Insulitis
A. Bioluminescence
B. Fluorescence imaging
C. Concluding remarks on optical imaging tech-
niques for imaging BCM and insulitis
IV. Nuclear Medicine Techniques for BCM Imaging
A. Imaging -cell secretory granules (Zn2-mediated
secretory vesicle formation
B. Imaging ATP-sensitive potassium channels
C. Imaging neurotransmitter targets on -cells
D. Imaging vesicular monoamine transporters type 2
(VMAT)
E. Imaging presynaptic vesicular acetylcholine
transporters
F. Imaging -cell metabolic pathways
G. Imaging GLP-1 receptor (GLP-1R)
H. Imaging -cells with islet cell-specific antibodies
I. Imaging -cells using radiolabeled peptides
J. Concluding remarks on nuclear medicine tech-
niques for -cell imaging
V. Nuclear Medicine Techniques for Imaging Insulitis
A. Labeled lymphocytes
B. Interleukin-2
C. Labeled antibodies
D. [18F]Fluorodeoxyglucose
E. Concluding remarks on nuclear medicine tech-
niques for insulitis imaging
VI. General Conclusions
I. Introduction
The pancreas is a small elongated organ nestled deeplyin the retroperitoneum between the duodenum,
stomach, and spleen. Themajority of the pancreas ismade
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up of exocrine cells. Dispersed within the normal adult
human exocrine pancreatic tissue, there are approxi-
mately 1 million distinct microanatomical structures
with proper portal-like vasculature and innervation.
These structures are known as islets of Langerhans and
account for less than 0.005% of the adult body weight.
Endocrine -, -, -, and PP cells are situated within
these islets. The -cells are the insulin-producing cells
and account for approximately 70–80% of the cells in
the islets of Langerhans.
In addition, a nonexocrine and nonendocrine compo-
nent is present that is made up of endothelial cells, para-
sympathetic, sympathetic, and sensory nerve cells, and
cells of hematopoietic origin (e.g.monocytes anddendritic
cells).
Insulin-dependent (type 1) diabetes mellitus (T1D) is a
metabolic disease with complex multifactorial etiology
and a poorly understood pathogenesis. Genetic and envi-
ronmental factors may cause an autoimmune reaction
against pancreatic -cells. Indirect evidence for autoim-
munity in humanT1D relies on the detection of insulitis in
autopsy samples (Table 1), on the presence of anti-islet-
cell antibodies, onT-cell response to-cell antigens, on the
associationofdiabeteswitha restricted set of class IImajor
histocompatibility complex (MHC) alleles, and on the fre-
quent association with other autoimmune disorders such
as celiac disease, thyroiditis, vitiligo, and rheumatoid ar-
thritis (1–3).
Examination of islet tissue obtained from pancreatic
biopsies of patients with recent onset T1D confirmed
the presence of insulitis in most, but not all, patients.
The presence of infiltrating CD4 and CD8 T lym-
phocytes, B lymphocytes, and macrophages suggests
that an inflammatory process has a role in the destruc-
tion of the -cells (4).
The generally accepted model of the natural history of
T1D suggests several distinct stages startingwith a genetic
susceptibility, thenautoimmunitywithout clinical disease,
and finally clinical diabetes (1). Nevertheless, other sub-
types of T1D have been hypothesized, including the ful-
minant T1D, which is accompanied by rapid massive de-
struction of -cells probably as a consequence of a viral
infection (5, 6).
Most of the pathogenetic hypotheses rely on studies
performed in two animalmodels of spontaneous diabetes:
BB/W rats (7–10) and nonobese diabetic (NOD) mice
(11–14).
In the autoimmune type of T1D, the appearance of
autoantibodies is the first sign and precedes several
months or years of -cell destruction, followed by the loss
of the first-phase insulin response to the iv glucose toler-
ance test. The progression to overt diabetes resulting in
significant -cell destruction is triggered by the develop-
ment of a more aggressive T-cell infiltration and a change
in the T-helper lymphocyte 1, T-helper lymphocyte-2
(Th1/Th2) balance toward a more proinflammatory state
(Table 1) (4). When clinical symptoms start, the autoim-
mune process is already markedly advanced. The -cell
destruction rate, however, is variable, being generally
more rapid in children than in adults (15). The exact
amount of living and functional -cells at the onset of
clinical symptoms is still unknown because of the lack of
an accurate method to quantify functional -cell mass
(BCM) in humans (16). However, some reports suggest
that at the time of diagnosis, as much as 60–80% of the
BCM can already be dead or dysfunctional.
It therefore emerges that: 1) the availability of a non-
invasive tool to quantify the extent and the severity of
pancreatic insulitis could be useful to understand the re-
lationship between the autoimmune phenomena and the
progression toward disease onset (17), for early diagnosis
of children at risk to develop overt T1D and to select pa-
tients to be treatedwith immune therapies aimed at block-
ing the insulitis process, and finally, tomonitor the efficacy
of these therapies; and 2) the possibility to quantify BCM
changes during the early progression of diabetes would
also provide important biological insights and facilitate
aspects of diagnosis and therapy, including islet cell trans-
plantation (18).
Because of the high clinical relevance of studying insu-
litis and BCM in vivo, a lot of effort has been put into this
research field. Despite that, the ideal imaging tool has not
beendevelopedyet,which ismainlydue to threeproblems:
1) the pancreas is not easily accessible by biopsy, thus
hampering histological approaches; 2) the islets of Lang-
erhans represent only 2–3% of pancreatic tissue and are
spread throughout the pancreatic parenchyma, although
more abundant in the pancreatic tail (19, 20); and 3) in-
sulitis is a chronic asymptomatic process of unknown ex-
tent in the prediabetes stage in humans.
When suitable noninvasive imaging techniques become
available, high-risk individuals could bemonitored before
onset of diabetes and over the course of their disease to
determine the natural history of the disease and the re-
sponse to therapy (18).
Structural (anatomical) imaging techniques [magnetic
resonance imaging (MRI) and computed tomography
(CT)] using specific contrast agents could theoretically
achieve the resolution needed to image BCM and insulitis
(21). However, until now, it has not been possible to pre-
cisely quantify BCM and insulitis with these diagnostic
imaging techniques. The major problems are: 1) the small
size of the islet and the scattered location in the whole
pancreas; 2) the small inflammatory lesion during the in-
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TABLE 1. Presence of insulitis and -cells at T1D onset
Patients (n) Sex (n)
Age at
diagnosis (yr)
Duration
of disease Insulitis
Other
markers
Remaining
-cells Ref.
4 M (1), F (1) 1 1 wk  ? 186
M (1) 10 1 wk 
M (1) 17 3 wk 
4/4 (100%)
21 M (2), F (1) 1 15 d  ? 149
M (1) 1 3 months 
M (2), F (2) 3 2 months 
M (2), F (1) 6–13 1 month 
F (2) 15 3 months 
M (1), F (3) 16 4 d 
M (1) 17 1 d 
M (2), F (1) 20–30 14 d 
11/21 (52%)
11 M (2), F (1) 3 4 wk   187
F (1) 10 8 wk  Degranulated
F (1) 11 8 wk 
F (1) 15 1 wk 
F (1) 17 3 wk 
M (3) 25–30 1 wk 
M (1) 31 1 wk 
6/11 (54%)
9 M (2) 2 8 wk  (1),  (1)  188
M (2) 3 4 wk  
F (1) 4 6 wk  
F (1) 5 12 wk  
M (1) 8 8 wk  
M (1) 11 2 wk  
F (1) 12 3 wk  
8/9 (89%) 9/9 (100%)
1 F (1) 12 1 month  HLA–I hyper, CD8  147
1/1 (100%)
47 M (11), F (15) 10 9 months  HLA–I hyper, HLA–DR  147, 148
M (5), F (8) 10–15 6 months  
M (4), F (4) 16–19 6 months  
47/47 (100%) 47/47 (100%)
18 M (3), F (3) 3 3 months  ? 147, 189a
M (1) 5 
M (2), F (1) 6–8 
M (2) 10–11 
F (2) 12–14 
M (1) 16 
M (3) 17–21 
19/19 (100%)
1 M (1) 22 2 d  Increase of small lymphocytes
and decrease of eosinophils
/ 190
1/1 (50%)
7 M (4) F (3) 24 4 months  HLA–DR hyper 4/7 (57%) 191a
88 ? 1–37 2 wk   192
88/88 (100%) 84/88 (95%)
18 M (11) F (7) 18 7 wk  CD8, CD4, HLA–I hyper / 193a
8/18 (44%)
1 M (1) 19 1 wk  HLA–I hyper, CD8 ? 194
1/1 (100%)
2 F (1) 1 1 month  ? 195
M (1) 3 1 wk 
2/2 (100%)
17 M (11) F (6) 18 1 month  HLA–I hyper ? 196a
8/17 (47%)
(Continued)
894 Di Gialleonardo et al. Insulitis and -Cell Imaging Endocrine Reviews, December 2012, 33(6):892–919
sulitis process; and 3) the lack of information about -cell
functionality and immune cell activity.
However, recent advances innoninvasive imaging tech-
niques such asmolecular studies applied toMRI, positron
emission tomography (PET), and optical imaging indicate
that there could be a role for diagnostic imaging in the
evaluation of -cell number, mass, and function and lym-
phocyte infiltration/inflammatory activity in T1D (22).
With the current functional imagingmethodology, the sin-
gle islet cannot be spatially resolved. Therefore, the islet
cells or the islet-infiltrating lymphocytes must be chemi-
cally resolvedwitha specific probe thathashigh specificity
for target combined with a low background signal. Thus,
the target should retain the labeled probe at least 1000-
fold more avidly than the surrounding exocrine cells, re-
sulting in sufficient contrast between the exocrine and en-
docrine pancreas (23). In addition, the probe should be
metabolically stable in circulationand showsuitable phar-
macokinetic properties. Combined structural and func-
tional imaging might be a suitable approach to overcome
the weaknesses of each individual technique. There is a
vast amount of literature concerning BCM and insulitis
imaging. In this review, we will outline the imaging tech-
niques currently available for in vivo, noninvasive inves-
tigation of BCM and insulitis.
II. Radiological Techniques for Imaging BCM
and Insulitis
Considering its anatomic location, the propensity for au-
tolytic damage, and the distribution of islets within the
exocrine tissue, pancreatic biopsies to quantify the BCM
and/or detect the insulitis are not easily performed. Diag-
nostic imaging of the endocrine pancreas is also problem-
aticmainly for thedifficulties todetect isletsofLangerhans
in the pancreatic parenchyma.The radiologicalmodalities
for pancreatic imaging includeMRI, ultrasound (US), and
CT (21).
A. Magnetic resonance imaging
MRI is a noninvasive approach that offers high spatial
resolution, especially in comparison with nuclear medi-
cine techniques and high intrinsic contrast in vivo. It is a
promising technique for islet imaging because it can target
possible -cell-specific components, using various mech-
anisms for contrast enhancement and achieving high-res-
olution images (24) with prolonged visualization of the
labeled cells. In fact, the MRI contrast agents do not have
theproblems related to theuse of radionuclides (decay and
short half-life) and may allow imaging over a long period
of time. Although it remains to be determinedwhether the
sensitivity and applicability of MRI are sufficient for hu-
man clinical applications, MRI has showed very promis-
ing results in animal models in the study of insulitis, pan-
creatic BCM, and islet transplantation.
Early biomarkers of pancreatic insulitis that can be in-
vestigated byMRI are the islet microvascular dysfunction
and the alteration in vascular volume, flow, and permea-
bility, as described in several models of T1D.
Usingaparamagneticcontrastagent,gadoliniumdiethylene
triaminepentaacetic acid-fluorinated (PCG-GdDTPA-F),with
high plasma half-life, detectable on T1-weighted MR ac-
quisition, it was possible to evaluate in vivo vascular
changes in a streptozotocin-inducedmousemodel ofT1D,
demonstrating a significantly higher accumulation of gad-
olinium diethylene triamine pentaacetic acid-fluorinated
in the pancreas of diabetic animals comparedwith normal
animals (25).
A specificmagnetic nanoparticle (MNP) [monocrystal-
line iron oxide nanoparticles (MION-47)] for MRI has
been proposed to identify and quantify the vascular vol-
ume and permeability changes associated with inflamma-
tion of the pancreas during the development of autoim-
TABLE 1. Continued
Patients (n) Sex (n)
Age at
diagnosis (yr)
Duration
of disease Insulitis
Other
markers
Remaining
-cells Ref.
1 F (1) 65 1 yr  DR4, CD4, CD8 ? 197a
1/1 (100%)
29 ? Mean 28 yr 3 months  CD8, aberrant HLA–I ? 198a
17/29 (58%)
2 ? Children Acute onset  CD45R, CD56, CD3 ? 199
2/2 (100%)
Summary
277 M  F 0–37 (one of 65 yr) 0–1 yr 223/270 (82.6%) HLA–I, HLA–II, CD3, CD4,
CD8, CD45, CD56
144/151 (95.4%) 17 papers
F, Female; M, male; HLA-I, human leukocyte antigen class I; HLA-II, human leukocyte antigen class II; HLA-DR, human leukocyte antigen class DR; CD, cluster
differentiation antigens; hyper, hyper-expression.
a Detected by biopsy.
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mune diabetes in rodents (NOD/Lt, E16/NOD, and
BDC2.5/NOD mice). This method relies on the measure-
mentof themicrovascular changes associatedwith inflam-
mation, and it is not hampered by the variations in MHC
alleles or autoreactive T-cell specificities that limit other
experimental approaches (26). The pancreatic inflamma-
tion can also be detected using long-circulating phago-
tropic nanoparticles that extravasate from the leaky ves-
sels into the surrounding tissue and are engulfed by
infiltrating inflammatory cells, particularlymacrophages.
Because MNP are superparamagnetic and thus negative
T2-weighted contrast agents, signal changes of pancre-
atic parenchyma (reduction of signal intensity) on T2-
weighted scans as a surrogate for vascular leak/macro-
phage uptake were used. Improvement of this approach
has been done using nanoparticles with a superparamag-
netic ironoxide (SPIO) core coatedwithdextran (27).This
modification can reduce immunogenicity of the particles
and increase blood resident time. A potential application
of this imaging technique is monitoring acute changes in
pancreatic inflammation in patients who have previously
undergone intervention trials to treat or preventT1D (26).
The second approach to monitor changes during the
progression of diabetes is to follow ex vivo lymphocytic
accumulation in the pancreas. Tracking labeled autoreac-
tive T lymphocytes was used to detect in vivo chronic
mononuclear cell infiltration into the pancreas during the
prediabetic phase. This approach is based on the intracel-
lular labeling of lymphocytes with superparamagnetic
contrast agents (dextran magnetic particles), which are
taken up by the cells by membrane diffusion. To increase
the uptake of nanoparticles inside the cells, the nanopar-
ticles can be modified to increase their hydrophobicity or
can be encapsulated into liposomes (28).
Dextran-coated SPIO nanoparticles coupled with
peptides encoding for the membrane translocation sig-
nal of HIV-1 (CLIO-Tat) were used to label lympho-
cytes with an efficacy of internalization that was 100
times higher than normal particles. After 30-min incu-
bation, the nanoparticles have not only entered the cell
but were also bound to the nucleus and nucleolus (nu-
clear accumulation) (29, 30).
Therefore,CD8 lymphocytes labeledwith thesenano-
particles were used to track the immune cells in animal
models of T1D. After adoptive transfer of nanoparticle-
labeled T cells into the recipient animal (NOD, Scidmice),
it was possible to visualize the labeled T lymphocytes in-
filtrating the pancreas by the signal intensity decrease in
the pancreatic parenchyma on T2-weighted images. The
decrease of pancreatic parenchyma signal onT2-weighted
images due to lymphocytic infiltration was not present in
control animals without insulitis. To improve these re-
sults, specific subpopulations of diabetogenic lympho-
cyteswere isolated from transgenicNODmice and loaded
withCLIO-NRP-V7-coated superparamagnetic nanopar-
ticles. These particles specifically bind to T-cell receptor 
on NRP-V7-reactive CD8 T cells. The labeled lympho-
cytes allowed the visualization in real time of the progres-
sive accumulation of NRP-V7-reactive CD8 T cells into
the pancreas of NOD mice (31). The target of this lym-
phocyte subpopulation is the islet glucose-6-phosphatase
catalytic subunit-related protein, and consequently, this
selected population of lymphocytes should selectively mi-
grate into the pancreas. Because islet glucose-6-phospha-
tase catalytic subunit-related protein is also present in the
human islets, this approach might allow translation of
results to human imaging.
There is only one recent report in humans that describes
the use of MNP as a contrast agent for MRI in T1D to
image insulitis. Gaglia et al. (32) evaluated 10 patients
with T1D and 12 nondiabetic controls. They used MRI
MNP previously validated in mouse models, ferumox-
tran-10, which has a dextran coating and size similar to
those used in animal experiments. These particles are
takenupbymacrophages anddonot induce cell activation
or proinflammatory cytokine or superoxide anion pro-
duction. MRI can detect MNP that migrate from the
leaky vessels into the surrounding tissue (extravasation)
and are phagocytized by inflammatory cells, particu-
larly by macrophages. MNP are negative T2-weighted
contrast agents because they induce changes in T2 signal
of pancreatic parenchyma (reduction of signal inten-
sity) as a surrogate parameter for measuring vascular
leak and macrophage content. The results of the study
by Gaglia et al. (32) showed that T1D patients at the
time of diagnosis already have a reduced pancreatic vol-
ume compared with controls and showed heterogeneity
in MNP accumulation. Although not testable in this
small study, one could speculate that such differences
reflect heterogeneity in the insulitis process itself.
Therefore, this technique requires further development
to determine its sensitivity and specificity (32).
Most MRI studies have been performed for imaging
BCM and transplanted islets in animal models of T1D.
Gimi et al. (33) used manganese (Mn), a contrast agent
forMRI with T1-relaxation properties, as a tool to image
in vitro-cell functionality in cell culturesof isolated islets.
Similar to calcium, extracellular Mn was taken up by glu-
cose-activated-cells, resulting ina200%increase inMRI
contrast enhancement vs. nonactivated cells. This scien-
tificwork can be considered the firstmolecularMRI study
for -cell imaging. After this study, several other ap-
proaches were tested.
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Nevertheless, most MRI studies have evaluated the ef-
ficacy of islet transplantation to replace-cell loss in T1D.
MRIcanmonitor islet transplantationanddetect causesof
islet failure.
Although islet transplantation is a promising therapeu-
tic approach, substantial islet loss can occur due to allo-
rejection, autoimmune attack, glucose toxicity, mechan-
ical stress, and microvascular disruption of the islets
during their isolation from the donor and their transplan-
tation. The strategies to visualize with MRI the phenom-
ena relevant to islet transplantation involve labeling of
isolated isletswith a contrast agent and their transplantation
into the recipient. In the first experience (34), purified pan-
creatic islets labeled with a commercially available SPIO
(Bayer Schering Pharma, Leverkusen,Germany)were trans-
planted through theportal vein into the liver of experimental
rats. The labeled pancreatic islets were clearly visualized in
the liver of both diabetic and healthy rats as hypointense
areas on T2-weighted MR images for a long period.
The labeling procedure facilitates detection and mon-
itoring of the transplanted islets, but we should make the
following considerations: 1) labeled nonfunctioning islets
cannot be distinguished from functioning ones, and there-
fore, transplantationof labeled islets does not directly pro-
vide any information on the function, short-termviability,
or absolutemass of-cells (35); 2) some phenomena, such
as gradual islet mass replacement by amyloid, cannot be
detected by the describedmethods unless the agent used to
label pancreatic islets is specifically designed to label
-cells; and 3) these methods were mainly used in small
animals, and there is just one report concerning its appli-
cation in humans by Toso et al. (36).
This study by Toso et al. (36) demonstrated the feasi-
bility and safety of MRI-based islet graft monitoring in
clinical practice byMRI of transplanted islets labeledwith
ironnanoparticles.Here, isolated isletswere culturedwith
SPIO nanoparticles for 24–72 h to obtain cell uptake via
random endocytosis.
Kriz et al. (37) investigatedMRI of labeled islets trans-
planted in the liver of diabetic rats and concluded that
iron-labeled pancreatic islets can be used for the detection
of the decreasing relative islet mass due to rejection.
Nevertheless, this methodology could not be easily ap-
plied to quantitative studies, and another approach was
tested: the use of automatic quantitative ultrashort echo
time imaging protocol. This protocol gives a positive
enhanced contrast to labeled cells, suppressing liver and
small vessel signal, thus allowing a precise in vivo quan-
tification of iron-labeled pancreatic islets transplanted
into the liver (38).
Heparinized SPIO nanoparticles (heparin-SPIO) were
also synthesized for chemical labeling of -cell surface as
proposed by Jung et al. (39). Compared with typical cel-
lular labeling with SPIO via endocytosis, surface labeling
with heparin-SPIO was shown to be more stable and im-
proved in animalmodels thehypointensity of transplanted
islets on T2-weighted MR images due to surface modifi-
cation of each islet.
The MRI detection of islet labeled by iron oxide-
based contrast agents and transplanted into the rat liver
parenchyma could be significantly improved using the
iv administration of a suitable contrast agent, gadolinium-
benzyloxypropionictetra-acetate (Gd-BOPTA), beforeMRI as
proposed byHerynek et al. (40).
On the labeling of endothelial progenitors of islet cells,
there is only one report focused on the use of contrast agent
gadolinium(phen)HDO3A (Gd-HDO3A), a paramagnetic
contrast agent that is visualized on T1-weighted images.
With this approach, authors demonstrated in vitro and in
vivo the visualization of isotransplanted mouse islets under
the mouse kidney capsule and xenotransplanted human is-
lets in the mouse liver (41).
B. Ultrasonography
USimaging isoneof themostusedmethodsfor theclinical
anddiagnosticevaluationof thepancreasdue to its safety (no
ionizing radiation exposure for the patient), high availability
in clinical settings, and relative ease of use.
The applications of US to medical imaging cover dif-
ferent diagnostic aspects: the anatomical structure of the
pathological organs and their functionality by dynamic
visualization of the organ blood flow.
Several anatomical and structural changes that occur in
the pancreas during T1D can be used for diagnosis of
diabetes mellitus, although US is rarely used in daily rou-
tine for this purpose.
The lack of visualization and quantification of the islets
of Langerhans is a major drawback of US that can detect
pathological changes only of the entire organ caused by
atrophy of the pancreatic islets and by several other alter-
ations. Its use in T1D is therefore limited.
In a series of studies, the pancreas in T1D patients was
shown to be smaller than in the healthy controls, and one
of the causeswas found to be the atrophy of islets of Lang-
erhans. In T1D patients, the thickness of head, body, and
tail is 1.9 0.3, 0.9 0.2, and 1.4 0.2 cm, respectively,
whereas in age-matched normal subjects, the thickness is
2.4 0.4, 1.1 0.3, and 1.8 0.4 cm, respectively. The
size of the pancreas is not correlated with the age of the
patient, but the decrease of the pancreatic volume is more
evident during the first year of T1D, involving particularly
the head/body and tail/body (42–44).
Even if US has been proved to be useful in detecting the
morphological change in the pancreas of diabetic patients,
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it is nowadays not possible to visualize any change before
the clinical onset of the diseases.
Recently, the possibility to use US as a noninvasive
method for the detection of intraportal islet transplanta-
tionwas investigated. Themain finding was the induction
of focal fatty infiltration, steatosis of the liver, which is
easily detectable with US (45).
Enhancement of the signal-to-noise ratio was better
achieved by tissue harmonic imaging (THI), a new tech-
nology that improves the image quality compared with
conventional US (46). THI is based on the phenomenon of
nonlinear distortion of an acoustic signal through the
body.Harmonicwave frequencies are higher-integermul-
tiples of the transmitted frequency, much like the over-
tones of a musical note. Current technology uses only the
second harmonic for US imaging. The processed image is
formedwith use of the harmonic-frequency-bandwidth in
the received signal after the transmitted frequency spec-
trumis filteredout.THIprovidesbetter axial resolutionby
using high frequencies without compromising depth pen-
etration. It is particularly useful for imaging cystic lesions
and those lesions containing highly reflective tissues such
as fat, calcium, or air. Harmonic imaging is particularly
helpful in obese patients because of the reduction of the
defocusing effect of the body wall. Therefore, in patients
with abodymass indexof 30kg/m2ormore,THI is clearly
better than conventional US, allowing better detection of
all abdominal organs, including the pancreas.
Promising results were obtained in the postoperative
monitoring of kidney/pancreas transplantation for the
evaluationofpancreasgraft rejection.Betterdetectionand
demarcation of pancreas graft was found (91 vs. 78% of
conventional US in T1D patients) (47). The limit of this
technique is its low accuracy.
C. Computed tomography
CT is another radiological imaging technique used to
visualize anatomicalmodificationsof a retroperitoneal or-
gans, such as the pancreas, and is based on the differential
attenuation of x-ray by different tissues (48, 49).
The islets of Langerhans are small, almost homog-
enously distributed throughout the exocrine pancreas and
have a similar density as the rest of the pancreas. There-
fore, it has not been possible yet to discriminate the islet
from the exocrine pancreas using the available CT scan-
ners. The recent availability of 256 and 512multidetector
high-resolutionCT scanners opens newpossibilities to the
study of the pancreas, although the slightmodifications of
the pancreatic parenchyma in termsof alterations in blood
vessel density and lymphocytic infiltrationduringdiabetes
are probably too small to effectively discriminate the
healthy from the pathological pancreas.
Advances in CT detector technology can now take ad-
vantage of the polychromatic nature of the x-ray spectrum
when creating CT images (spectral CT imaging). In dual-
energy CT, the simultaneous use of two different-energy
x-rays allows the differentiation of tissues on the basis of
their energy-related attenuation characteristics. Spectral
CT can therefore facilitate the discrimination of tissues,
making it easier to differentiate betweenmaterials, such as
tissue containing calcium and iodine that can appear sim-
ilar on traditional monochromatic CT techniques. More-
over, this technique could reduce x-ray radiation dose and
is hypothesized to increase imaging sensitivity to contrast
agents. Improving the sensitivity of CT to low amounts of
contrast agentmay enable the use of novel contrast agents,
allowing CT to provide molecular and physiological in-
formation (50) aswell as to evaluate pancreatic perfusion.
CT has also been used to visualize the modifications
that occur after pancreas or kidney-pancreas transplan-
tation for treatment of T1D. After transplantation, there
are usually modifications in the surrounding tissue, such
as fat infiltration (steatosis), altered vessel organization,
thrombosis, andacute lymphocytic infiltrationof lympho-
cytes (51).These changes reflect strongmodificationof the
density and vascularity of the organ that can be detected
by contrast-enhanced CT.
In conclusion, nowadays, CT is not suitable to visualize
BCM and insulitis during the natural history of diabetes,
but this technique holds good promise for the future.
D. Concluding remarks on radiological techniques for
imaging BCM and insulitis
MRI,due itshigh spatial resolution, is themostpromising
radiological technique for imagingBCMand insulitis. There
are newnanoparticles that canbeused to visualizeBCMand
insulitis, thus allowing the identification of islet pathologies.
It also offers the important advantage over CT of avoiding
radiation exposure and being the technique of choice to fol-
low up children at risk for diabetes.
US has no major role for -cell and insulitis imaging.
CT, using new technologies, could be a good alternative to
image morphological alterations after pancreatic trans-
plantation, but it cannot be used for imaging insulitis.
III. Optical Imaging Techniques for Imaging
BCM and Insulitis
Optical imaging (bioluminescence and fluorescence imag-
ing) was developed as a new strategy to study molecular
and biological events, such as cell trafficking, apoptosis,
protein-protein interactions, etc.Optical imaging is based
on the use of labeled molecules that emit photons with a
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specific wavelength that is detectable outside the body
with sophisticated instruments.
Recently, optical imaging was applied to study T1D
because it can potentially give quantitative and spatial
information about islets in the pancreas.
A. Bioluminescence
Bioluminescence imaging (BLI) hasbeen investigatedas
a noninvasivemethod to quantify and visualize BCM.The
strategy was to develop a transgenic construct with a spe-
cific promoter that regulates the expression of a reporter
gene (i.e. luciferase enzyme) in the target cells. For diabetes
research, the reporter genewas placedunder control of the
mouse insulin promoter (MIP) (52). Consequently, the
expression of the reporter gene was induced only in pan-
creatic-cells of transgenicmice thatproduced insulin and
contained this construct. In -cells that expressed the re-
porter gene, the enzymatic reaction between the reporter
enzyme (luciferase) and a substrate (luciferin) produced
photons that canbe capturedbya charge-coupleddetector
camera (53). The bioluminescent signal emitted by the
cells expressing the transgene is specific for -cells, no
signal is observed in other tissues, and an excellent corre-
lation was found between the bioluminescent signal and
the number of islets (r20.986).Moreover, the activity of
luciferase increased 2.5-fold in hyperglycemic conditions,
indicating that bioluminescence is also correlatedwith the
metabolic status of the cells. In addition, no auto-biolu-
minescence occurred in normal tissues, meaning that a
high target-to-background ratio can be obtained. The
good correlation between the luciferase expression and
cellular condition makes the BLI a good candidate for
-cell imaging. -Cells transfected with luciferase under
control ofMIPwere successfully applied to followupgraft
rejection after islet transplantation.
In case of syngeneic transplantation of 250 tagged islets
in FVB/Nj mice, the signal decreased by 46% in the first 2
wk after transplantation, but after this period, the signal
remained constant for 160 d. After allogeneic islet trans-
plantation in BALB/c streptozotocin-induced diabetic
mice, the bioluminescent signal decreased by 55% at d 19
after the islet inoculation. Immunohistochemistry con-
firmed that CD3 T cells were responsible for the graft
rejection after transplantation.
The sensitivity of this BLI technique was investigated
also in animals transplanted with 10–150 tagged islets in
different parts of the body (liver, subcapsular renal space,
ip, and sc). The strongest signal was obtained when islets
were inoculated sc. These results underline the main dis-
advantage of optical imaging, attenuation of photons by
tissue, which hampers the detection of signals fromdeeply
located tissues and organs (54). Consequently, this tech-
nique is applicable only to small animals or superficial
tissues.
B. Fluorescence imaging
Fluorescence imaging is based on the use of specific
molecules labeled with a fluorophore. The migration of
the labeledmolecules in tissues is subsequently monitored
using a dedicated camera or microscope (55).
The fluorescent label must be irradiated with an exter-
nal light source with an appropriate wavelength to bring
the fluorophore to an excited state. Subsequently, the fluo-
rophore will return to its ground state and emit light with
a longerwavelength.Themost common fluorophore is the
green fluorescent protein (GFP) that emits a green light
with a wavelength of 509 nm (56, 57).
There is a growing list of other fluorophore such as a
Cy5.5, quantum dots, and near-infrared probes. Fluores-
cent probes have been used in microscopy as a tag for the
subcellular localizationof biomolecules under normal and
pathological conditions. Recently, the possibility to use
these fluorescent molecules to visualize different cell sub-
types in vivo in animalmodelswas also explored (58–60).
TheGFP gene was put under control of a -cell-specific
promoter, such as MIP, to induce the tissue-specific expres-
sion of the fluorescent probe in -cell cultures (61–63).
In 2003,Hara et al. (64) generated transgenicmicewith
stable and specific expression of GFP in -cells. Prelimi-
nary data indicated that it is possible to quantify BCM ex
vivo using fluorescence-activated cell sorter analysis. In
addition, this strategy was applied to isolated -cells by a
cell sorter toobtain apurepopulationof-cells expressing
GFP for in vitro studies.
This genetically engineeredmousemodel could be used
to study -cell development from the embryonic stage to
the adult stage. In addition, this model was suitable to
study the three-dimensional distribution of islets in the
pancreas and to quantify the BCM during the different
stages of diabetes (64).
Major limitations of fluorescence imaging are the au-
tofluorescence of endogenous biomolecules, such as he-
moglobin and collagen, and the light absorption by sur-
rounding tissues, causing an increase in the background
signal and a reduction in the target signal, respectively.
Near-infrared fluorophores aremore promising thanGFP
because they suffer less from autofluorescence or absorp-
tion by tissues.
Recently, Reiner et al. (65) published a study about the
measurement of BCM using exendin-4 conjugated with
the near-infrared fluorophore (VT750) thatwas produced
via copper-catalyzed click chemistry. This fluorescent
probe (E4X12-VT750) is able to selectively bind to the
glucagon-like peptide receptor subtype 1 (GLP-1), which
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is expressed on -cells. Intravital microscopy, histology,
and endoscopy proved that there was an excellent corre-
lation between islet area and islet size with the VT750
fluorescent signal (R2 0.944 and 0.992, respectively). A
good correlation between BCM estimated with immuno-
staining for insulin and the VT750 fluorescent signal
(R2  0.854) was also observed.
Optical techniques are new methods to visualize BCM
in research settings, but these techniques cannotbeapplied
in humans because of the limited penetration of light
through tissues.
C. Concluding remarks on optical imaging techniques for
imaging BCM and insulitis
Optical imaging offers excellent possibilities for imag-
ing both BCM and insulitis. This has been well docu-
mented in animal models, particularly for time-course
studies.
The application of these techniques in humans is ham-
pered by the deep location of the pancreas in the body and
by the difficulty of detecting fluorescent light with the
currently available technology.
IV. Nuclear Medicine Techniques for
BCM Imaging
Several approaches have been used to image -cells with
radioactive probes, as summarized in Table 2 and Fig. 1
and described below in detail.
A. Imaging -cell secretory granules (Zn2-mediated
secretory vesicle formation)
Zn2 plays a critical role in the biosynthesis, trans-
port, maturation through the Golgi apparatus, and se-
cretion of insulin. Zinc ions are essential for packaging
insulin into the secretory vesicles by formation of hex-
amers of insulin, which are ready to be released upon
glucose demand (66, 67).
Dithizone (DTZ) is currently used as a dye for histo-
logical examination and to monitor cell survival in vitro.
Latif et al. (68) have studied the mechanism of staining
-cells with DTZ. DTZ permeates the cell membrane and
complexeswithZn2 in the secretory vesicles and remains
stored in the granules of pancreatic -cells. In 1988, Latif
and co-workers (68) demonstrated that DTZ is able to
stain specifically pancreatic islets.
Later, Fiedor et al. (69) used an iodine DTZ analog to
radiolabel ex vivo the islets of Langerhans isolated from
healthy Lewis rats. These DTZ-labeled islets were synge-
neically transplanted in the renal subcapsular space of di-
abetic recipients and were shown to have a long-term sur-
vival. Because DTZ is a potentially toxic compound, the
correlation between the doses injected, the time from in-
jection, and the toxicity was studied in vivo. At low con-
centrations and at short intervals after DTZ administra-
tion, no side effects of this radiopharmaceutical were
found in target cells. DTZ administration does not inter-
fere with the normal endocrine function of -cells (69–
71). Encouraged by these results, other studies were per-
formed that explored the possibility to use DTZ labeled
with a radioisotope for in vivomonitoring of the viability
of the pancreatic islets.
The most frequently used isotope for labeling DTZ is
131I, although labeling yields were poor. In addition,
[131I]DTZ is an unstable compound in biological fluids.
To stabilize the radiopharmaceutical, Garnuszek et al.
(72) have developed a new radioiodination procedure that
produced a more stable radiolabeled compound: 2–2-di-
carboxy dithizone-[131I]histamine. It possessed the ability
to bind Zn2, creating a stable complex that is trapped in
the secretory vesicles of-cells.Moreover, the in vivo tests
in Wistar rats showed a high pancreatic uptake [12.41 
2.33%of the injecteddose (ID)/g tissue] after injection in the
splenic artery with blockade of the liver artery. However,
when the radiolabeledDTZwas injected into the tail vein of
the rats (thus allowing liver metabolism of DTZ) the uptake
in the pancreas was very low (0.81 0.27% ID/g) (72).
Recently, a radioactive fluorinated DTZ analog was
synthesized for PET imaging. [18F]DTZ was tested in in
vitro and in vivo studies to evaluate specific uptake and
retention. Three different cell types have been used in
vitro: isolated-cells from rats, an exocrine pancreatic cell
line, and an endocrine cell line. The data suggest that the
uptake was nonspecific, because radiopharmaceutical
binds in both the endocrine and the exocrine cell lines.
Moreover, the retention of the radiopharmaceutical in the
pancreas was low in vivo and was comparable to that in
other organs. Significant uptake was also found in the
spleen, stomach, lungs, heart, and fat, resulting in a low
signal-to-background ratio (73).
Taken together, these results indicate that uptake of
radiolabeled DTZ is low and not exclusive for -cells.
Moreover, the toxicity of this compound may be another
hurdle for its use in patients (74). Therefore, DTZ is not a
good candidate as a probe for noninvasive imaging of
-cells.
B. Imaging ATP-sensitive potassium channels
ATP-sensitive potassium channels are present on the
surface of many kinds of neuroendocrine cells including
-cells (75).
ATP-sensitive potassium channels on -cells are com-
posed of two different subunits. The first one is a small
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potassiumchannel,Kir 6.2, that formsapore and contains
the ATP-binding site. The second is the regulatory sulfo-
nylurea receptor (SUR) with an intracellular Mg nucleo-
tide activation site (76).
In -cells, only the SUR1 subtype was identified. SUR1
is a large trans-membrane protein belonging to the ATP-
binding cassette protein superfamily with two intracellu-
lar nucleotide-binding sites. The complete ATP-sensitive
potassium channel is formed by four Kir 6.2 and four
SUR1 subunits (77). This channel regulates the insulin
release in response to changes in plasma glucose concen-
tration through the integration of signals from different
pathways, such as changes in membrane potential and
ATP levels (78).
TABLE 2. Radiopharmaceuticals used for -cell imaging
Radiopharmaceutical Isotope Type of study Target Pros Cons Ref.
DTZ 131I Animal studies -cell secretory
granules
High pancreas
accumulation
Isotope, low LE, unstable 69, 72
DTZ 18F In vitro and
animal studies
-cell secretory
granules
High uptake and
specificity for -cells
Low retention 73
Repaglinide 11C In vitro studies -cell SUR1 High affinity for SUR1 Low LE, lack of
quantitative data
82
Repaglinide 18F In vitro studies -cell SUR1 High affinity for SUR1
(lower as compared
with 11C	repaglinide)
Low LE, low accumulation
in -cells
83
Glibenclamide (glyburide) 3H In vitro studies -cell SUR1 High uptake, high
specificity for -cells
Isotope features, low
specific activity, low
retention
86
Glibencamide (glyburide) 18F In vitro and
animal studies
-cell SUR1 and
-2
Low uptake in vivo on
pancreas, low specificity
87
Naphthylalanine
derivatives
123I In vitro and
animal studies
sstr2 High accumulation in the
pancreas
Low affinity for the
receptor
94, 95
L-DOPA 3H In vitro and in
vivo studies
AADC Specific accumulation in
vivo on -cells
No selectivity in vitro for
-cells
103–105
Dopamine 3H In vitro studies AADC Water solubility, rapid
clearance, low plasma
protein binding
Moderate selectivity for
-cells
73
Serotonin 3H In vitro studies -cell secretory
granules
Low uptake and retention
in -cells, low specificity
104, 109
5-HTP 11C In vivo studies Large amino
acid
transporter
(LAT)
Stored in secretory
granules
110, 111
DTBZ 11C Animal studies/
human studies
Ligand for
VMAT2
High target-to-
background ratio
Short half-life 116, 118
DTBZ 18F Animal study Ligand for
VMAT2
High pancreatic uptake Uptake in surrounding
organs (high
background activity)
115, 120
4-Fluorobenzyltrozamicol 18F Animal and
human (1
patient)
studies
Presynaptic
vesicular
acetylcholine
transporter
High uptake Low specificity for -cells 123
FDG 18F In vitro studies -cell metabolic
pathway
Low specificity for -cells,
low uptake
73, 126
Nicotinamide 14C In vitro studies -cell metabolic
pathway
High retention Low uptake, low -cell
specificity
73
GLP-1 125I In vitro studies GLP-1R High and specific uptake
on -cells
Lysosomal degradation 135
Exendin-3 68Ga In vivo studies GLP-1R High and specific uptake
in -cells
Preliminary data 136
Lys40-(Ahx-
DTPA)exendin-4
111In In vitro and
animal studies
GLP-1R High uptake No specific binding on -
cells
137, 138
Anti-IC2 mouse
pancreatic -cell (IC2
MoAb)
111In Animal studies IC2 antigen -cell specificity Slow clearance and
uptake, no quantitative
data
141, 142
MORF/cMORF 99mTc Animal studies TAG-T2 High specificity for -cells Intestinal uptake 143
MORF/cMORF 111In Animal studies TAG-T2 High specificity for -cells Preliminary data 143
MoAb, Monoclonal antibody; LE, labeling efficiency.
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When the glucose concentration in plasma is high, the
ATP-sensitive potassium channels are closed, resulting in
a membrane depolarization that opens the voltage-sensi-
tive Ca2 channels. The result is an influx of Ca2 into the
cell, which stimulates the exocytosis of intracytoplasmic
vesicles, in which insulin is stored. In this way, glucose
homeostasis is maintained (77). In recent years, several
hypoglycemic drugs have been developed that bind to
ATP-sensitive potassium channels. Most of the sulfonyl-
urea drugs used for diabetes treatment act at low concen-
trations by inhibiting the SUR subunit (79). The new gen-
eration of sulfonylureas, which specifically target -cells
without strong side effects, can be used as lead compound
for developing PET and single-photon emission CT
(SPECT) radiopharmaceuticals.
1. Repaglinide
Repaglinide is a drug that binds to the SUR (80, 81).
Repaglinide was labeled with 18F by alkylation with
2-[18F]fluoroethyl tosylate and with 11C by 11C-methyla-
tion. Both radiopharmaceuticals were prepared in high
radiochemical yield (20 and 35%, respectively) and had a
high radiochemical purity (98 and99%, respectively).
For both compounds, binding assays were performed
to determine the affinity of the radiopharmaceutical for
the SUR. For these experiments, COS-1 cells that express
Figure 1.
Figure 1. Schematic structure of a pancreatic -cell showing relevant receptors that have been targeted by different radiopharmaceuticals for -cell
imaging.
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the human SUR1 on the cell surface were used.Moreover,
insulin secretion experiments on rat islets were performed
to test the functionality of this compound in vitro.
These experiments showed that [11C]repaglinide binds
with high affinity and specificity to SUR1. Because the
molecular structure of the 11C-labeled radiopharmaceu-
tical is identical to the structure of repaglinide, and its
biological activity is also identical to that of the unlabeled
drug (82).
[18F]Repaglinide shows lower specific binding than
[11C]repaglinide, suggesting that the fluoroethyl groupde-
creases the binding affinity and the biological activity. De-
spite the lower specific binding of [18F]repaglinide com-
pared with the radiopharmaceutical labeled with 11C, a
biodistribution study in rats was performed. The results
indicated that 10–30 min after injection, there is a stable
accumulationof this radiopharmaceutical in the pancreas,
suggesting that [18F]repaglinide has potential for human
PET imaging (83).
2. Glibenclamide
Glibenclamide (glyburide) is a second-generation sul-
fonylurea. Compared with first-generation drugs, it is
more efficient at lowglucosebloodconcentrations andhas
fewer side effects. Glyburide has the same mechanism of
action as repaglinide, but it is three to five times more
effective (84, 85).
Glyburide was first labeled with tritium for in vitro
studies to determine the specificity, accumulation, and re-
tention in INS-1 -cells and PANC-1 exocrine pancreas
cells as control. Freshly isolated-cells from rat isletswere
also used. The uptake of [3H]glyburidewas high in-cells,
but not specific, because high uptake was also found in
exocrine cells, which do not express SUR1. The study also
showed that [3H]glyburide uptake decreased in the pres-
ence of albumin, thus making this radiopharmaceutical
not suitable for in vivo imaging (86).
Despite these disappointing results, [18F]glyburide was
synthesizedand tested in two-cell lineswithgood results.
When the cells were preincubated with an antibody
against SUR, decreased [18F]glyburide binding was ob-
served, indicating that the binding is receptor mediated.
This radiopharmaceutical was not tested in an exocrine
cell line, and therefore, its specificity for -cells was not
determined.
Normal and streptomycin-induced diabetic SCIDmice
were used to determine the usefulness of this radiophar-
maceutical in vivo. Pancreatic uptake was low, and the
background signal was high in both groups of animals.
This could be due to the binding of glibenclamide to SUR1
and SUR2 with similar affinity. SUR2 is also expressed in
other tissues such as cardiac, smooth, and skeletal muscle,
thus increasing the background signal. Control experi-
ments, where the radiopharmaceutical was administrated
after injection of an excess of unlabeled glibenclamide,
showed that the radiopharmaceutical uptake was not
blocked and therefore not specific (87). One of the main
problems of glyburide is its high lipophilicity causing high
nonspecific binding and plasma proteins.
Recently, Schneider et al. (88) have studied a new gly-
buride-glucose conjugate. Binding affinity studies were
performed in COS-1 cells transfected with human SUR1,
but the new glycosylated compound showed lower bind-
ing affinity than the nonglycosylated drug. However, the
glyburide-glucose conjugate has 40% less activity for
stimulation of insulin secretion compared with the non-
glycosylated compound. Glycosylation also increases the
molecule’s hydrophobicity and plasma clearance, thus de-
creasing nonspecific binding and accumulation in liver
and intestine. Consequently, an improved signal-to-noise
ratio was obtained, which is beneficial for the detection of
pancreatic islet cells in vivo.
Among the aforementioned radiopharmaceuticals,
glyburide-glucose conjugate appears the most useful for
-cell imaging, but further evaluation of the compound is
still required.
C. Imaging neurotransmitter targets on -cells
Somatostatin, dopamine, and serotonin receptors and
metabolic enzymes for these neurotransmitters are ex-
pressed not only in the central nervous system (CNS) but
also in -cells. As a consequence, these proteins might be
potential targets for molecular imaging of BCM (Fig. 2).
1. Somatostatin receptor imaging
The somatostatin receptor type 2 (sstr2) is localized in
all pancreatic cell types, but it is most abundant in -cells.
High expression of various subtypes of the receptor was
also found in pancreatic tumors (89).
Radiolabeled somatostatin analogs are currently used
for diagnosis and staging of neuroendocrine tumors ex-
pressing sstr (90). Among the somatostatin analogs that
have been radiolabeled are octreotide (91), lanreotide
(92), and vapreotide (93), which bind to several sstr sub-
types with different affinity. These analogs have been la-
beled with several radioisotopes, which give them differ-
ent characteristics in terms of stability and imaging
resolution. So far, however, these radiopharmaceuticals
have not been applied for imaging BCM.
Amartey et al. (94) have synthesized a new iodinated
nonpeptide compound based on -naphthylalanine and
n-hexanediamine. The radiopharmaceutical shows low
affinity for sstr2, butbiodistributiondata innormalCBA/J
mice showed that there is a high accumulation of this ra-
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diopharmaceutical in the pancreas (18.0  0.5% ID/g),
which could partially be blocked by administering an ex-
cess of the unlabeled compound. These results indicate
that the uptake in the pancreas is receptor mediated, al-
though it may involve another receptor than the sstr. The
selectivity of this radiopharmaceutical was evaluated also
in CHO cells that expressed either sstr1 or sstr2. The re-
sults showed that the affinity of the radioiodi-
nated compound is higher for sstr1 than sstr2.
When comparative biodistribution studies in
NOD mice and control CBA/J mice were per-
formed, a significantly lower uptake of the ra-
diopharmaceutical was observed in 8- to 16-
wk-old NOD mice compared with control
mice. Moreover, in 26-wk-old NOD mice,
hardly any uptake in the pancreas was detect-
able, which probably reflects the progressive
decrease of BCM caused by the progression of
diabetes. It should be noted that the uptake of
this radiopharmaceutical was also high in or-
gans that surround the pancreas, such as small
intestine, liver, spleen, and kidney, hampering
imaging quality of BCM (95).
2. Dopamine synthesis
L-3,4-Dihydroxyphenylalanine (L-DOPA)
is a drug that is used for the treatment of
Parkinson’s disease and Parkinson’s disease-
related disorders (96–98). L-DOPA is effi-
ciently converted into dopamine by the enzyme
amino acid decarboxylase (AADC) (99). L-DOPA
has been labeled with 11C and 18F for PET im-
aging of the integrity of dopaminergic system in
the neurodegenerative disorders, because the
L-DOPA uptake correlates with the density of
dopaminergic neurons (100, 101). [18F]DOPA
has also been successfully used for PET imag-
ing of neuroendocrine tumors, like carcinoids,
because these tumors have a high expression of
AADC (102). AADC is also expressed in the
granules of pancreatic -cells, and therefore,
this enzymecouldbe investigatedas a target for
-cell imaging. Indeed, pancreatic accumula-
tion of radiolabeled L-DOPA was investigated
in mice. It was shown that tritiated L-DOPA
accumulated selectively in pancreatic -cells
and other islet cells. Microscopic autoradiog-
raphy showed that the radioactivity was pre-
dominantly localized in the secretory granules.
Inhibition experiments proved that L-DOPA
accumulation in the pancreas was AADC me-
diated (103–105).
Sweet et al. (73) have tested the in vitro up-
take and retention of tritium-labeled L-DOPA and dopa-
mine in pancreatic -cells. In contrast to the aforemen-
tioned in vivo experiments, dopamine showed moderate
selectivity for -cells over control cells in these in vitro
experiments, whereas L-DOPA did not show any selectiv-
ity at all. These contradictory in vivo and in vitro results
Figure 2.
Figure 2. Schematic structure of an islet of Langerhans infiltrated by B and T
lymphocytes. The two drawings above show a T lymphocyte with radiopharmaceuticals
used for targeting T lymphocytes in vivo (top left panel) and a T lymphocyte with
radiopharmaceuticals used for labeling T lymphocytes in vitro (top right panel). In the first
approach, the radiopharmaceutical is injected iv and binds to infiltrating cells in tissues.
With the second approach, T cells are purified in vitro from peripheral blood, labeled,
and then reinjected iv to migrate into the inflammatory site.
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require further investigation. 18F- and 11C-labeled
L-DOPAhave not been investigated for-cell imaging yet.
3. Serotonin
Serotonin receptors are predominantly expressed in the
CNS, especially in the thalamus, hypothalamus striatum,
and frontal cortex. Serotonin receptors are also found in
tissueswithneuroectodermic origin (endocrine cells) and tis-
sues with extensive innervation, such as the gastrointestinal
tract (106). The serotonin receptors in the pancreas are sim-
ilar to those in the CNS, and all subtypes of serotonin recep-
tor are expressed on the -cell surface (106, 107).
Serotoninergic neurons, -aminobutyric acid (GABAe-
rgic), glutamic-acid decarboxylase (GAD)-containing fibers
are dense in periductal cells and periislet. In spontaneous
animalmodels of T1D, i.e.NODmice and BB/W rats, a loss
of sympathetic nervesduring theprogressionofdiabeteswas
shown.For instance, there is a severe nerve loss in10-wk-old
NODmice that show the first symptoms of diabetes (108).
Several PET radiopharmaceuticals have been devel-
oped for monitoring the distribution, density, and func-
tional state of serotonin receptors in the CNS, including
[11C]WAY100635, 4-(2-methoxyphenyl)-1[2-(N-2
-pyridi-
nyl)-p-[18F]fluoro-benzamido]ethylpiperazine ([18F]MPPF),
and [18F]altanserin, but none has been used for imaging
BCM. Only [3H]serotonin was used to investigate the feasi-
bilityof labeled serotoninanalogs for-cell imaging. Invitro
autoradiography of the pancreas incubated with [3H]sero-
tonin showed radioactivity associated with -cell secretory
granules. Blocking studies with an AADC inhibitor reduced
the number of grains that were visualized by autoradiogra-
phy (104).
[3H]Serotonin was also used in cell experiments with
exocrine cells (PANC-1), endocrine cells (INS-1), and pri-
mary cell cultures from isolated rat islets. [3H]Serotonin
uptake was about twice as high in the endocrine cell line
and cultures from freshly isolated islets than in the exo-
crine cells (73). Thus, imaging with labeled serotoninmay
be an interesting approach to monitor BCM, and indeed,
recently, Deeney et al. (109) found a good correlation be-
tween insulin secretion and [3H]serotonin uptake in INS-1
cells (endocrine -cell line).
This observation could have interesting implications
for imaging with [11C]5-hydroxytryptophan ([11C]HTP),
the precursor of serotonin, which is successfully used for
imaging neuroendocrine and islet-cell tumors (110, 111).
[11C]HTP is taken up by neuroendocrine cells via the large
amino acid transporter and converted into serotonin by
the enzyme AADC and then stored in secretory granules.
Therefore, [11C]5-HTP could be a good candidate for im-
aging the decrease of BCM during diabetes progression,
although more investigations are needed.
D. Imaging vesicular monoamine transporters type
2 (VMAT)
VMATareATP-dependent transporters that regulate the
uptake of monoamines from cytoplasm into secretory gran-
ules in neuroendocrine cells. This system is preferentially ex-
pressed in catecholinergic, serotoninergic, andhistaminergic
neurons as well as in endocrine cells (112). At the moment,
there are only two known isoforms of this transporter,
VMAT1 and VMAT2. The differential expression of
VMAT1 and VMAT2 in neuroendocrine tissues was inves-
tigated by immunohistochemical analysis and in situhybrid-
ization. In the pancreas, VMAT1 is expressed in duct cells,
and it is not expressed in the pancreatic islets. In contrast,
VMAT2 is preferentially expressed in -cells but not in glu-
cagon- and somatostatin-producing cells (113). In particu-
lar, it has been demonstrated that 88  4% of -cells are
positive for VMAT2 (29 15%of total islet cells), but also
39 7%of the exocrine duct cells are positive for VMAT2.
These results demonstrated the correlation between pancre-
atic islet-cells andVMAT2 expression, although the target
does not appear to be totally specific for -cells (114).
Dihydrotetrabenazine (DTBZ) is a ligand that selectively
binds to the VMAT2-binding site. Two radiopharmaceuticals
were developed for PET imaging of VMAT2, [11C]DTBZ,
and 18F-9-fluoropropyl-()-dihydrotetrabenazine, [18F]FP-
DTBZ.Historically, labeledDTBZwas used for PET imaging
of the VMAT2 in the CNS of patients with neurodegenerative
diseases,whereadecreaseduptake isobservedduetothe lossof
monoamine neurons (115). Simpson et al. (116) have demon-
strated that the [11C]DTBZ is a promising PET radiopharma-
ceutical for -cell imaging. [11C]DTBZ was studied in Lewis
rats treated with streptozotocin (STZ) as a model for diabetes
and in normal euglycemic rats as a control group. STZ induces
apoptosis in -cells, resulting in an increase in glucose concen-
tration in blood. If the glucose concentration is above 300mg/
ml, the rats are considered diabetic. PET imaging showed that
the uptake of [11C]DTBZ is decreased significantly (P 0.05)
in STZ-induced diabetic rats compared with the euglycemic
controlrats.VMAT2andproinsulinmRNAwerequantifiedby
real-time quantitative RT-PCR. Animals treated with STZ
showed lower relative abundance of VMAT2 and proinsulin
transcripts and decreased functionality and viability of -cells.
These data suggest that [11C]DTBZ uptake is correlated with
the presence of VMAT2 expression on -cells. Longitudinal
noninvasive PET studies in BB/W diabetes-prone rats with
[11C]DTBZwereperformedbySouzaandco-workers (117) in
an attempt to image BCMdecline with time. The studies were
started in 4-wk-old animals, when they were still euglycemic,
and continued until the animalswere diabetic. Results showed
agoodcorrelationbetweenthepancreaticradiopharmaceutical
uptake of [11C]DTBZ and VMAT2 expression (r2  0.58),
which declined during disease progression. Interestingly, a sig-
Endocrine Reviews, December 2012, 33(6):892–919 edrv.endojournals.org 905
nificant reduction of pancreatic uptake was already detectable
beforetheappearanceofhyperglycemia,thussuggestingtheuse
ofthisradiopharmaceuticaltopredictdiabetesbeforeitsclinical
onset.
Cross-sectional human studies were also performed in
nine control healthy volunteers and six patients with
long-lasting T1D. The pancreatic binding potential of
[11C]DTBZ in patients was only 14% lower than in
healthy controls. Because BCM in patients with advanced
disease is minimal, a larger reduction in the diabetic pa-
tients’ pancreatic binding potential was expected. The
small reduction in radiopharmaceutical uptake could be
explained by a nonspecific radiopharmaceutical uptake in
the exocrine portion of the pancreas and by the presence
of a radioactive [11C]DTBZ catabolite. Despite the fact
that animal studies arepartially indisagreementwith stud-
ies in humans, more studies are needed to clarify the over-
estimation of pancreatic radiopharmaceutical uptake in
patients (117–119). Taken together, these results suggest
that DTBZ may not be sensitive enough to monitor
changes of BCM in the early stages of the disease.
Because of the short half-life of 11C, a fluorinated an-
alog of DTBZ was also developed, which can be distrib-
uted to nuclear medicine centers that do not have a cyclo-
tron for 11C production. Like [11C]DTBZ, [18F]FP-DTBZ
was primarily used for studyingVMAT2-positive neurons
in the brain.
Recently, a first preliminary study on imaging of-cells
with [18F]FP-DTBZwas published. Kung et al. (115) have
demonstrated in rats that [18F]FP-DTBZ has potential as
a radiopharmaceutical for -cell imaging. Biodistribution
and small-animal PET imaging studies in normal rats
showed that the uptake of [18F]FP-DTBZ in the pancreas
was maximum at 30 min after injection (5.50  0.97%
ID/g). The data also showed significant uptake in the or-
gans around the pancreas, such as liver, spleen, andkidney
(2.82  0.24, 1.03  0.18, and 1.06  0.06% ID/g, re-
spectively), but uptake in these organs was lower than in
pancreas. Blocking studies with FP-()-DTBZ and ()-
DTBZ were performed to confirm specific binding of flu-
orinated DTBZ to VMAT2. There was a significant re-
duction in uptake of [18F]FP-DTBZ after the treatment
with both unlabeled compounds, demonstrating that the
binding of [18F]FP-DTBZ is specific. Pretreatment with
the inactive enantiomer did not result in a significant re-
duction of radiopharmaceutical uptake,whichmeans that
radiopharmaceutical uptake is stereo-selective (115). Fi-
nally, a preliminary study in human pancreatic islet ho-
mogenates demonstrated high-affinity binding of [18F]FP-
DTBZ to its specific target. Finally, Eriksson et al. (120)
have investigated the feasibility of using [18F]FE-()-
DTBZ as a probe for BCM in human T1D and T2D tissue
slices. They demonstrated that the binding of the radio-
pharmaceutical to its target is not specific, with high ac-
cumulation in the exocrine pancreas. Animal studies
showed significant defluorination as indicated by high
bone uptake. Thus, [18F]FE-()-DTBZdoes not appear to
be a suitable radiopharmaceutical for the detection and
quantification of BCM.
E. Imaging presynaptic vesicular acetylcholine
transporters
Themaintenanceof glucosehomeostasis is regulatedby
an interplay between different factors, such as the glucose
concentration,autonomicnervoussystem,systemicgrowthfac-
tors,andautocrineandparacrineactionsofmoleculesproduced
by -cells.
The peripheral autonomic nervous system regulates
many physiological functions including the endocrine ap-
paratus. Within the pancreas, the cholinergic system is
found predominately in the periphery of the islets, where
it regulates -cell function. Several studies demonstrated
the presence of choline acetyltransferase andacetylcholine
esterase activity in islet cells, suggesting an important role
of the cholinergic system in the regulation of insulin se-
cretion. Acetylcholine plays a central role in insulin secre-
tion in the absorptive phase via M3 muscarinic receptors
on pancreatic -cells (121, 122).
N-[18F]Fluorobenzylatrozamicol is a radiopharmaceu-
tical that binds specifically to the vesamicol receptor as-
sociatedwith the vesicular acetylcholine transporters. Pre-
liminary data showed an excellent pancreatic uptake
between 10 and 90 min after [18F]fluorobenzylatrozami-
col injection, but there was also a significant salivary
gland, liver, and gallbladder uptake. In T1D, cholinergic
innervation is reduced, and it will be interesting to further
study this radiopharmaceutical in this disease (123).
F. Imaging -cell metabolic pathways
1. Fluorodeoxyglucose (FDG)
The introduction of [18F]FDG for PET imaging has rev-
olutionized the clinical diagnosis of several pathologies.
The most important use of this radiopharmaceutical is in
diagnosis, staging, and therapy evaluation in cancer (124,
125). Nevertheless, Sweet et al. (73) used FDG labeled
with tritium for preliminary in vitro studies to image
-cells, but the compound was not selective for -cells,
because therewas high accumulation and retention also in
exocrine cells. In 2005, the feasibility of [18F]FDG as a
probe to image the islets of Langerhanswas explored. The
aim of this study was to follow the cell trafficking and the
fate of islets after intraportal transplantation. Results
showed that radioactivity in the liver was higher after islet
transplantation than in controls.Amajor problemwas the
906 Di Gialleonardo et al. Insulitis and -Cell Imaging Endocrine Reviews, December 2012, 33(6):892–919
radiopharmaceutical washout, because 50% of activity
was released from the islets every hour after the injection
(126). In 2007, Eich et al. (127) applied hybrid PET/CT to
visualize transplanted porcine islets labeled with [18F]FDG
after intraportal infusion. Only 50% of the infused radio-
activity was found in the liver 20 min after injection, in-
dicating that significant loss of islets already happens soon
after transplantation. The immediate action of the innate
immune system (complement system) on the transplanted
islets, or hypoxia-induced cell death, could explain the
huge loss of islets after transplantation. Moreover, a het-
erogeneous distribution of the radioactivity in the liver
was observed, defined as a hot spot, which represents
groups of islets trapped in the portal branches of the liver.
In 2009, the same group confirmed that transplanted
islets are not distributed uniformly in the liver, but are
distributed differently between the segments and lobes of
the patient’s liver. Moreover, they were able to quantify
the distribution pattern of transplanted islets by PET/CT
(128). In conclusion, a dynamic PET/CT investigation
could be useful for quantitative and qualitative analysis of
islet survival after transplantation, but [18F]FDG is not a
suitable candidate for imaging the residual BCM in TD1
patients.
2. Nicotinamide
Nicotinamide is a molecule that belongs to the B3 vi-
tamins family. Nicotinamide protects the cell from reac-
tive oxygen species and nitric oxide and probably im-
proves cell regeneration (129).
In mice treated with STZ, nicotinamide prevents the
reduction of nicotinamide adenine dinucleotide in pan-
creatic islet cells.
Autoradiographic studies, using [3H]2-deoxyglucose
and [14C]nicotinamide showed that these compounds
compete for the same transporter (glucose transporter 1).
Nicotinamide has the same trans-membrane transport
mechanism as 2-deoxyglucose (130). Nevertheless, Sweet
et al. (73) have demonstrated in vitro that the uptake of
[14C]nicotinamide in islet pancreatic cell lines and exo-
crine pancreatic cell lines is not significantly different.
Thus, labeled nicotinamide does not appear to be a suit-
able tool for -cell imaging.
G. Imaging GLP-1 receptor (GLP-1R)
GLP-1R is a G protein-coupled receptor that binds the
incretin hormones released from the intestinal tract during
digestion. These receptors are important in the regulation
of glucose homeostasis, through insulin, glucagon, and
somatostatin secretion. GLP-1R triggers an important in-
tracellular signaling pathway for the -cell proliferation
and differentiation (131, 132). Binding studies showed
that this receptor is widely distributed in several organs. It
is located in brain, hypothalamus, stomach, heart, intes-
tine, kidney, and pancreatic islets (133). Colocalization
studies of insulin, glucagon, somatostatin, and pancreatic
polypeptide with GLP-1R mRNA and protein demon-
strated that GLP-1R expression is restricted to the -cells,
whereas the level of receptor expression on - and -cells
is below the detection limit. Weak and heterogeneous im-
munoreactivity was also observed in the pancreatic duct
membrane (134). There are several ligands that can bind
the receptor: GLP-1, GLP-1mimetics, exendin-4, and sev-
eral new compounds with higher biological half-life and
higher resistance to the inactivation by proteases (131).
These pharmaceuticals are used forGLP-1-based therapy,
and at present,GLP-1 analogs have attracted the attention
of nuclear medicine physicians for their possible role as
-cell imaging probes.
To this purpose, GLP-1 was labeled with 125I. This ra-
diopharmaceutical was tested in an insulinoma cell line
(RINm5F) in vitro and in vivo (NEDH rats inoculated
with RINm5F cells). Both experiments showed high and
specific uptake, but a serious problemwas the high lysosomal
degradation rate of the radiopharmaceuticals (135).
At present, studies are in progress to increase the sta-
bility of these labeled proteins. For example, dipeptidyl
peptidase IV can be inhibited to prevent the cleavage of
GLP-1 in body fluids and thus to increase its biological
half-life. Recently Brom et al. (136) reported the develop-
ment of a new radiopharmaceutical, Lys40-(DOTA)exen-
din-3 labeled with 68Ga. There was a specific and high
uptake in a sc INS-1 insulinoma, and high uptake in the
kidney was found, because of the renal clearance of the
radiopharmaceutical. This new radiopharmaceutical
might be also used to image BCM in T1D, but this has not
been investigated yet. For clinical applications, however,
a stable peptide with better biological properties may be
required. For this purpose,Wild et al. (137) investigated a
GLP-1 analog designed to be more stable in human serum
than other GLP-1 ligands. Lys40-aminohexanoic-diethyl-
enetriaminepentaacetic acid (Ahx-DTPA)-NH2-exten-
din-4was labeledwith 111In and tested inRip1Tag2 trans-
genic mice. This labeled peptide proved to be more stable
than radiolabeled GLP-1 and exendin-3. More than 80%
of radiolabeled exendin-4 remained intact in human se-
rum after 4.5 h. The biodistribution of this radiopharma-
ceutical showed high uptake in insulinoma, the target tis-
sue for this radiopharmaceutical.Anduptakewas reduced
more than 95% when the animals were treated with an
excess of the unlabeled ligand. High radiopharmaceutical
uptake was also observed in the kidney, but this uptake
was not specific, because it was not blocked by the unla-
beled ligand. The tumor-to-pancreas uptake ratio for this
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radiopharmaceutical was extremely high, 13.6 at 4 h after
radiopharmaceutical injection. In2010, Pattou et al. (138)
published a case report describing the successful clinical
application of radiolabeled exendin-4 for imaging autol-
ogous islets transplanted in the brachioradialis muscle.
One year after transplantation, focal accumulation of
[Lys40-(Ahx-DTPA111In)-NH2]exendin-4 was still visible
in the transplantation site. These results provide clinical
evidence thatGLP-1 analogs couldbeuseful for islet trans-
plantation imaging. Whether pancreatic uptake of the ex-
endin-4 analog is sufficient for BCM imaging remains to
be investigated. Although pancreatic -cells express high
levels of GLP-1R, it might be difficult to visualize them
with this radiopharmaceutical because of the limited res-
olutionof SPECTand the small sizeof thepancreatic islets.
We can conclude that the GLP-1 analogs are promising
peptides for-cell imagingdue their high specificity for the
-cells, but a PET radiopharmaceutical may be required.
To this purpose, exendin-3was labeledwith 68GabyBrom
et al. (136), as described above. Because 68Ga is only a
partial positron emitter, producing high-energy positrons,
perhaps even better image quality could be achievedwhen
a pure positron emitter such as 18F or 11C is used for
labeling. Gao et al. (139) recently published the first 18F-
labeled PET radiopharmaceutical for GLP-1. These
authors labeled EM3106B, a GLP-1 analog, with 18F
through conjugation withN-2-(4-[18F]fluorobenzamido)
ethylmaleimide. The 18F-labeled EM3106B showed spe-
cific binding to the GLP-1R on insulinoma cells in vitro
and in vivo. Specific uptake in insulinoma in tumor-bear-
ing mice could be clearly delineated by PET. So far,
however, no reports on imaging of -cells with this PET
radiopharmaceutical have been published. Despite prom-
ising results so far, an intrinsic complication of this class
of radiopharmaceuticals for -cell imaging could be the
presence of the GLP-1R on the pancreatic duct cells in the
exocrine pancreas, which might obscure the signal origi-
nating from -cells, especially when BCM is reduced.
H. Imaging -cells with islet-cell-specific antibodies
Antibodies are heavy (150kDa) globular plasmapro-
teins known as Ig. They can recognize specific epitopes
through their variable regions. To quantify BCM, radio-
labeled antibodies need tobind to specific targetmolecules
selectively expressed on the -cell surface. Several -cell-
specific biomarkers are known, and specific antibodies
against these epitopes have been developed.
An interesting antibody is the IgM -monoclonal anti-
body IC2 against sulfatide expressed on the -cell surface.
Sulfatide is a glycosphingolipid localized in secretory
granules and on the plasmamembrane of-cells. Sulfatide
controls the secretion of insulin (140). No immunoreac-
tivity was found in frozen pancreas sections, because this
biomarker is highly sensitive to detergent, denaturant, and
other chemical reagents used during the staining treat-
ment. Several in vitro and in vivo studies with this anti-
body were done. IC2 was labeled with 125I for pharma-
cokinetic studies and with 111In for in vivo and in vitro
studies.
Experiments with these probes showed excellent up-
take and specificity of the radiopharmaceutical, but the
most interesting result was the high correlation between
accumulation of the labeled antibody in the pancreas and
the BCM in diabetic animals (r2 0.936) (141, 142). This
antibody is not commercially available, and only animal
studieswere performed so far due to the xenogeneic origin
of this IgM antibody. If this antibody was injected in hu-
mans, it would probably develop an immune reaction due
to its rat origin. The promising results obtained so far
warrant adaptation of the IC2 antibody for human use.
Another limitation of radiolabeled pancreatic antibodies
for imaging -cells is high background activity due to the
slow clearance of antibodies from circulation. This could
be done using only the variable region (Fv) of the antibody
or a humanized version of it.
So far, no other radiolabeled antibodies for imaging of
-cells have been reported.
I. Imaging -cells using radiolabeled peptides
Because of this slow plasma clearance, monoclonal an-
tibodies have to be labeled with long-lived isotopes, re-
sulting in a high radiation burden to the patient. To over-
come these limitations, pretargeting strategies could be
applied. First, pancreatic -cells are targeted by a specific
antibody, followed by the administration of a small la-
beled effector that specifically binds to the antibody pre-
viously injected (142). Liu et al. (143) report they used
CC49 as an antibody against tumor-associated glycopro-
tein 72, a glycoprotein expressed in a variety of adeno-
carcinoma and also present on the surface of -cells. They
modified the antibody by conjugation with a morpholino
oligomer (MORF). The effector is a complementary
MORF (cMORF) labeled with 99mTc or 111In. The results
of this approach were promising, with a high accumula-
tionof labeled cMORF in the pancreas. Themain problem
of [99mTc]cMORF was the high accumulation of this la-
beled effector in the intestines (2% of the total injected
dose). Thus, the quantification of the BCMwas hampered
by thehighbackgroundactivityaround thepancreas. In con-
trast, 111In-labeled cMORF did not show any intestinal ac-
cumulation (144). Therefore, the applicationof pretargeting
strategies for BCM quantification could be feasible using
111In-labeled cMORF, but further investigation is needed to
validate this new and promising methodology.
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J. Concluding remarks on nuclear medicine techniques
for -cell imaging
The design of a new radiopharmaceutical for imaging
-cells follows the histological identification of a specific
-cell antigen or a specific metabolic pathway. There are
also surrogates of BCM that can be targeted, such as neu-
rotransmitter receptors. Nuclear medicine techniques,
both SPECT and PET, do not have the special resolution
necessary for islet imaging, and therefore, nuclear medi-
cine probes may have a role in islet imaging only if they
provide a very high target/background ratio. The smaller
the anatomical structure to image, the higher must be the
target/background ratio (ratio between the radiopharma-
ceutical uptake in the endocrine and exocrine tissue). In
this context, the most promising radiopharmaceuticals
tested so far are serotonin receptor agonists and GLP-1
analogs, although competingwithMRI technology is abig
challenge.
V. Nuclear Medicine Techniques for
Imaging Insulitis
Insulitis is the lymphomononuclear cell infiltration of the
pancreatic islets, causing -cell destruction. Insulitis can
begin a long time before the clinical manifestations of di-
abetes and is the pathological hallmark of T1D (Table 1).
It is an autoimmune process regulated by many factors,
such as a genetic predisposition and environmental factors
(145). The current status of knowledge on T1D histopa-
thology is mostly based on old observations from the
1960s (146–149). The major problem for studying the
natural history of insulitis in humans is the limited avail-
ability of the pancreatic specimens from diabetic patients
and prediabetic subjects because of the difficulty in ob-
taining pancreatic biopsies and in identifying subjects at
risk to develop diabetes. Mostly postmortem pancreatic
material fromdiabetic patients has been analyzed to study
in detail the characteristics of insulitis (150). Histological
examination showed the presence of insulitis inmore than
50% of the T1D patients at the time of diagnosis, indi-
cating that the insulitis is a crucial aspect in the pathogen-
esis of diabetes. Because in the last decades many biolog-
ical therapies have been identified to modulate the
immune process in several autoimmune diseases, these
could also be applied in T1D if patients could be identified
before the complete destruction of BCM. Early diagnosis
of insulitis is, therefore, mandatory. New strategies are
needed to detect it, not only for prevention purposes but
also for therapy decision making and therapy follow-up.
From previous sections, we learned of the frustrating
attempts of radiological and optical techniques for imag-
ing lymphocyte trafficking in vivo in humans. This is
mainly due to the difficulty of coupling enough contrast
agent (or fluorescent dye) to lymphomononuclear cells to
produce a signal detectable from outside the body. Nu-
clear medicine, by using radiolabeled probes (with high
specific activity) that target specific cell antigens, is the
only concrete possibility to image insulitis in humans.
Probes for noninvasive imaging include labeled autol-
ogous lymphocytes, labeled cytokines, and labeled anti-
bodies and peptides against lymphocyte antigens and
FDG, as summarized in Table 3 and Fig. 2 and described
in detail below.
A. Labeled lymphocytes
Autoreactive T cells are implicated in the inductions
of -cell apoptosis during the prediabetic phase (151).
A direct approach to image insulitis can be the use of ex
vivo radiolabeled autologous lymphocytes. This implies
the purification of 40–100  106 autologous lympho-
cytes from peripheral blood, their in vitro labeling of
[111In]oxine (152–154), [111In]tropolonate (155, 156), or
[99mTc]HMPAO (hexamethylpropyleneamine oxime)
(157–159) and their iv readministration into the patient.
The assumption is that peripheral blood lymphocytes are
able to migrate to the affected tissue attracted by various
cytokines and chemokines and home there (160). Indeed,
lymphocytes from patients affected by T1D were labeled
with [111In]oxine and reinjected in the same patient. After
the autologous transfer, the homing of labeled lympho-
cytes into the pancreas was, however, poor. Only a few
patients were examined, and these data were never con-
firmed again by others (161). Others studied the homing
of labeled lymphocytes in BB/W rats by investigating the
pancreatic localization of autologous labeled lymphocyte
after reinfusion in diabetes-prone, resistant BB/W rats and
inWistar Furth rats. All groups of animals showed similar
lymphocyte uptake in the pancreas. There was no corre-
lation between the insulitis and the amount of lympho-
cytes localized in the pancreas (162). The interpretation of
these results was that only a few circulating cells are able
tomigrate into affected tissues during an autoimmune dis-
ease, whereas most cells migrate to the spleen and other
secondary lymphoid tissues. This was also investigated in
Hashimoto’s thyroiditis and Graves’s disease (160). An
alternative hypothesis is that ex vivo labeled lymphocytes
with [111In]oxine are damaged by the radiations and the
purification procedure and lose their migration capacity
when reinjected in vivo. Therefore, this technique was
abandoned but provided a basis for nuclear medicine im-
aging of insulitis.
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B. Interleukin-2
IL-2 is glycoprotein of 133 amino acids mainly pro-
duced by activated T lymphocytes. It plays a central role
in T-cell growth, survival, differentiation, and transcrip-
tional regulation. The IL-2 receptor consists of three sub-
units (-, -, and c-chain; respectively, CD25, CD122,
and CD132) with different binding affinities. The highest
affinity binding of IL-2 is with CD25 that can be present
as a trans-membrane or soluble receptor. CD122 is im-
plicated in the intracellular signal transduction, and
CD132 is a common chain-cytokine receptor (163, 164).
The intracellular pathway of the activation-transduction
of T cells needs the entire heterotrimeric complex formed
byall of the subunits.Thecomplex triggers an intracellular
signal through the activation of JAK/STAT, PI3K, and
MAPK pathways. These pathways lead to cell prolifera-
tion and increase the lymphokine secretion and MHC
class-II molecule expression. All of these properties are
important to regulate the immune response in autoim-
mune conditions (165).
Radiolabeled IL-2 was used for imaging of several
chronic inflammatory conditions, characterized by the
lymphomononuclear cell infiltration of CD25-positive
cells including T1D (166).
First, IL-2 was labeled with 123I. BB/W rats and NOD
mice were used as models of diabetes. BB/W rats have
characteristics that are closer to human insulitis, although
they show a lower degree of insulitis than NOD mice.
In NOD mice, radiopharmaceutical uptake could be
quantified well due to the high lymphocytic infiltration.
[123I]IL-2 showed good in vitro, in vivo, and ex vivo data,
including high specific binding, good retention, and good
correlation between the radiopharmaceutical uptake in
the pancreas and the severity of insulitis (167–170). This
radiopharmaceutical was tested in pre-T1D patients and
prediabetic subjects with high risk to develop this pathol-
ogy (islet serum markers were checked). [123I]IL-2 pan-
creatic uptake was clearly distinguished from the kidney
and spleen (17, 166).
Chianelli et al. (171) radiolabeled IL-2with 99mTc. The
first step of the labeling procedure is the conjugation of
IL-2 with N3S, and the second step is the labeling of con-
jugated product with 99mTc. The radiopharmaceutical
TABLE 3. Radiopharmaceuticals used for insulitis imaging
Radiopharmaceutical Isotope Type of study Target Pros Cons Ref.
Autologous lymphocytes 111In Animal studies in BB/W PBL Feasibility study Low uptake 162
Autologous lymphocytes 111In T1D at onset PBL PBL can home in the
pancreas
Toxicity on PBL, low
uptake, few patients
161
IL-2 123I In vitro and NOD and
BB/W rats pre-T1D
IL2R or CD25 Good binding in vitro to
TAC, ARG, good ex
vivo data, good
comparison with LA,
kinetics, and ARG;
good concordance
with metabolic
markers
Not ideal imaging tool,
very expensive;
pancreas ROI identified
by CT or MRI
166–170
IL-2 99mTc T1D, LADA, non-T1D,
pancreas cancer
IL2R or CD25 Good correlation with
clinical and metabolic
data, correlation with
histology
High liver uptake, few
LADA patients
172, 173
IL-2 18F Animal studies, BB/W
rats and NOD mice
IL2R or CD25 Linear correlation with
the diabetes
progression,
correlation with the
extent of insulitis
Preliminary studies 200
Human Ig 99mTc T1D and pre-T1D Fc receptor Good uptake and
results comparable to
IL-2
Long distribution time 176, 177
FDG 18F Animal studies GLUT 1 Good pancreatic uptake No correlation with the
degree of insulitis
182, 183
FDG 18F Newly diagnosed type
1 diabetes
GLUT 1 Good uptake correlated
and correlation with
the regression of
insulitis and
radiopharmaceutical
uptake
Weak methodology,
poor pancreatic
localization
184
GLUT1, Glucose transporter 1; IL-2R, IL-2 receptor; PBL, peripheral blood lymphocytes; ROI, regions of interest; TAC, T-activated cells; ARG, autoradiography; LA,
-lactalbumin; LADA, latent autoimmune diabetes.
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had a high specific activity (64 GBq/mol) and good re-
ceptor-binding properties. [99mTc]N3S-IL-2 was evalu-
ated in newly diagnosedT1Dpatients before and1 yr after
treatment with nicotinamide and insulin therapy. The re-
sults of these studies showed good pancreatic radiophar-
maceutical uptake due to the lymphomononuclear infil-
tration at baseline and a progressive uptake reduction
during the immunomodulatory treatment (172, 173). An
improvementof the labelingprocedureof [99mTc]IL-2was
achieved using the bifunctional chelating agent 6-hydrazi-
nopyridine-3-carboxylic acid, resulting in a simplified ra-
diolabeling procedure and an easily available stable com-
pound (174). [99mTc]6-Hydrazinopyridine-3-carboxylic
acid-IL-2 has not been evaluated as an insulitis imaging
agent yet. Radiolabeled IL-2 could be a promising radio-
pharmaceutical to detect infiltrating lymphocytes in insu-
litis. A major problem remains the low resolution and
sensitivity SPECT and the small size of the pancreatic
islets.
For that reason, recently, Di Gialleonardo et al. (175)
have synthesized a new radiopharmaceutical [18F]FB-IL-2
[N-(4-18F-fluorobenzoyl)interleukin-2 by conjugation of
N-succinimidyl 4-[18F]fluorobenzoate to lysine residues
in the IL-2 protein. Good stability in human plasma and
retention of the biological activity was observed. Prelim-
inary animal studies show good pancreatic uptake, but
additional animal studies are needed for a better evalua-
tion of this radiopharmaceutical.
C. Labeled antibodies
Antibodies can be divided in two groups: polyclonal
and monoclonal antibodies. Polyclonal antibodies are
nonspecific Ig that recognize the Fc receptor in the infil-
trating lymphocytes.
Humanpolyclonal Ig radiolabeledwith 99mTcwasused
successfully in many autoimmune diseases (176). Barone
et al. (177) proved that this radiopharmaceutical can be
used to detect the lymphomononuclear cell infiltration in
T1D patients. Moreover, this study demonstrates the fea-
sibility of selection of patients that can benefit from im-
munomodulatory therapy.
Malviya et al. (178) have recently published a non-Fc-
binding anti-CD3 monoclonal antibody labeled with
99mTc that was suitable for imaging of small numbers of T
lymphocytes in tissues.Likewise, themonoclonal antibod-
iesOKT3andanti-CD4werealso radiolabeledwith 99mTc
and 111In to target these specific receptors on the T lym-
phocyte surface (178–180). These antibodies were used
for imaging autoimmune diseases that are associated with
strong inflammatory reactions, although insulitis was not
investigated. For insulitis imaging, themainproblem is the
relatively lownumber of lymphocytes or the relatively low
number of antigens expressed on lymphocytes present in
the insulitis that can be detected with these radiopharma-
ceuticals. Indeed, the resolution of nuclear medicine tech-
niques stands mainly on the signal-to-noise ratio, and ra-
diolabeled antibodies are known for having a high
background, circulating activity.Also, the poor resolution
of SPECT could be another limiting factor, and the higher
resolution of PET could be advantageous. In this regard,
differently from cytokines, antibodies have a long biolog-
ical half-life (from 5–20 d) and consequently a long dis-
tribution time; therefore, PET isotopes,with short half-life
(11C or 18F), are not suitable for labeling antibodies, be-
cause the physical half-life of the isotope is much shorter
than the biological half-life of the antibody. Long-lived
isotopes, like 89Zn, could be useful but give rise to high
radiation exposure.
Despite promising preliminary data, labeled antibodies
still need to be validated as suitable candidates for imaging
of insulitis.
D. [18F]Fluorodeoxyglucose
Different inflammatory cell types exhibit increased glu-
cose metabolism in sites of inflammation during several
pathologies (181). The glucose pathway might be used
as a potential target to detect subacute and chronic
inflammation.
Kalliokoski et al. (182) investigated the feasibility of
[18F]FDG as a radiopharmaceutical for the detection of
infiltrating lymphocytes during insulitis in a diabetes-
prone animal model (NOD mice). They found a 2.3-fold
increase in radiopharmaceutical uptake in the endocrine
pancreas compared with the exocrine tissue. Similar up-
take was found in early-stage and late-stage insulitis, and
unfortunately, the islet-to-exocrine pancreas uptake ratio
did not correlate with the degree of the insulitis (r 
0.0068). In addition, animal studies in rats proved that
this radiopharmaceutical cannot be used as a probe to
detect the insulitis, probably due to the low lymphomono-
nuclear cell infiltration in the rat pancreas (182, 183). Still,
Kalliokoski et al. (184) continued the investigation in hu-
mans. Sixteen newly diagnosed T1D normoglycemic pa-
tients were chosen as a test group (assuming they still had
insulitis at time of diagnosis), and nine age-matched
healthy subjects were chosen as control group. The
[18F]FDG uptake in the pancreas of newly diagnosed di-
abetic patients was higher than controls and decreased
after 3–6 months of insulin treatment.
From these studies, we can conclude that [18F]FDG
could be used for imaging of insulitis, although combined
analysis with techniques that allow anatomical localiza-
tion of the pancreas may be required. Because inflamma-
tory cells can be labeled efficiently with [18F]FDG, Toso
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and co-workers (185) performed a study to assesswhether
leukocytes ex vivo labeled with [18F]FDG were able to
detect graft rejection after islet transplantation. This
study clearly demonstrated that leukocytes (mainly
granulocytes) labeled with [18F]FDG could not detect
inflammation after transplantation, most likely due to
the presence of lymphomononuclear cells in the inflam-
matory reaction. This technology therefore appears not
sensitive and specific enough to allow the visualization
or the quantification of the inflammatory response after
islet transplantation.
E. Concluding remarks on nuclear medicine techniques
for insulitis imaging
Similarly to the-cell imaging approach, the imagingof
islet-infiltrating cells requires the preliminary knowledge
of leukocyte antigens and of histopathology of the disease
during its natural history.Most of these data are available
from animal models and are extrapolated to humans with
some limitation.The relevant cells infiltrating the islets are
macrophages, cytotoxic T lymphocytes, and activated T
lymphocytes. There aremany different antigens expressed
on these cells, and only a few radiopharmaceuticals have
been designed to specifically target a few cells and anti-
gens. Results are encouraging, particularly using radiola-
beled IL-2, but this field of research needs to be further
explored in humans.
VI. General Conclusions
Type 1, or juvenile (insulin-dependent), diabetes is a met-
abolic disease associated with the autoimmune destruc-
tion of -cells. Because of the increase in the incidence of
this pathology, it becomes necessary to develop new di-
agnostic tools to quantify the residual BCM and the
chronic lymphocytic infiltration during the disease pro-
gression and in its preclinical phase.Until now, serological
evaluation of autoantibodies (glutamic-acid decarboxyl-
ase auto-antibodies, insulin auto-antibodies, islet anti-
gen-2 auto-antibodies) and indirect metabolic studies on
the functionality of -cells are performed after the clinical
onset of the diseasewhen the reductionof functional BCM
might already be advanced to 60–80%.Early diagnosis of
diabetes is necessary to design new therapeutic strategies
for decreasing the inflammatory reaction against the
-cells and to evaluate the residual BCM. The aim is to
block the activation of the immune system to keep the
BCM viable and prevent disease progression. The final
goal will be to develop a specific therapy that can improve
the quality of life of patients or even obtain diabetes
prevention.
For imaging BCM, the ideal method should discrimi-
nate between the endocrine and exocrine tissue (have a
high target-to-background ratio) and between functional
and nonfunctional -cells. In this review, we surveyed the
radiological, optical imaging, and nuclear medicine diag-
nosis methodology described until now. The major chal-
lenge is to find a technique that can combine specific tar-
geting for-cellswith the high spatial resolutionneeded to
localize the -cells in islets of Langerhans spread through-
out the pancreas parenchyma. With respect to the spatial
resolution, MRI is the most promising technique, being
noninvasive and with the highest spatial resolution and
good soft tissue contrast. However, this technique lacks
the specificity of the probes used to target -cells. By con-
trast, PET and SPECT techniques can exploit radiophar-
maceuticals with high specificity for -cells but lack of
resolution. Unfortunately, the ideal method/probe for im-
aging BCM is not available yet.
This review also highlights the available methods for
insulitis imaging. In this field, very littlehasbeenpublished
with radiological techniques, and all hopes reside in nu-
clear medicine techniques by the use of specific PET and
SPECT radiopharmaceuticals that bind in vivo to infil-
trating immune cells in the insulitis. Because insulitis is
characterized by the infiltration of activated T lympho-
cytes andmacrophages in the pancreas, several radiophar-
maceuticals that target inflammatory markers have been
investigated. Because insulitis is characterized by the in-
filtration of activated T lymphocytes and macrophages in
the pancreas, several radiopharmaceuticals that target in-
flammatory markers have been investigated. The possi-
bility to image the insulitis (i.e., the immune cells infiltrat-
ing the endocrine pancreas)may have an important role in
identifying subjects at risk to develop T1D in which to
start an immune therapy to delay or prevent the clinical
onset of the disease. The therapeutic modulation of insu-
litis requires surrogate markers to monitor the early effi-
cacyof these therapies. In this view, insulitis imaging could
be one of the most relevant of these surrogate markers.
These techniques could also help with therapy decision
making, selecting the best drug depending on the kind of
immune cells infiltrating the islets, and could help to fol-
low up the efficacy of preventive therapies. These tech-
niques could also help for therapy decision making, se-
lecting the best drug depending on the kind of immune
cells infiltrating the islets, and could help to follow up the
efficacy of preventive therapies.
Finally, methods that can allow us to detect insulitis or
BCMcould also be applied tomonitor graft rejection after
the islet or pancreas transplantation, which is the most
promising therapeutic procedure under investigation for
the replacement of -cell function.
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